UK to funnel $160 million into clinical research infrastructure

The funding will be spread over five years, between 2017 and 2022, for renewing investment in clinical research facilities after the current funding expires in March 2017.

By Ned Pagliarulo • Feb. 4, 2016

Allergan's Texas plant primed for expansion, possible job growth

There have been concerns (in some cases, justified) of big job cuts in the wake of Pfizer's proposed megamerger with Allergan.

By Nicole Gray • Feb. 4, 2016

FDA alleges deleted files, hidden data at India's Wockhardt

Upon inspection of Wockhardt's Shendra-based facilities, FDA employees found evidence of inaccurate record-keeping, deleted records, and improperly labeled and filed pharmaceutical ingredients. 

By Nicole Gray • Jan. 28, 2016

Pfizer recalls 3 lots of Lyrica after heat damage

The three lots of Lyrica were manufactured in Germany and have been recalled in the United States and Puerto Rico. 

By Ned Pagliarulo • Jan. 28, 2016

Specialty injectables maker Sagent considering buyout with Cipla, Dr. Reddy's, others

The U.S.-based injectables maker is reportedly being pursued by several major Indian drugmakers.

By Sy Mukherjee • Jan. 28, 2016

Cost control in the time of biopharma consolidation & globalization

Life sciences firms' wave of M&As and shifts abroad has catalyzed deals in other tranches of the supply chain, too.

By Sy Mukherjee • Jan. 21, 2016

Study: FDA scrutiny, other competition likely to eat into Indian pharma growth

FDA efforts to monitor manufacturing quality have already crimped exports from India. Additionally, other lower-cost emerging markets may begin to threaten India's role in the market, according to a study conducted by Assocham-TechSci Research. 

By Nicole Gray • Jan. 21, 2016

Pfizer reportedly mulling production expansion in Russia with Polysan

Other firms have also explored manufacturing plans in the economically beleaguered nation. But political turmoil has continued to be a hurdle. 

By Sy Mukherjee • Jan. 21, 2016

Chinese pharma company slapped with import ban by FDA

Zhejiang Hisoar Pharmaceutical is the 41st Chinese pharma manufacturer added to the import ban list.

By Ned Pagliarulo • Jan. 21, 2016

Off-label use of Avastin in India hospitalizes 15, sales halted in two states

Roche's Avastin is commonly used off-label to treat wet age-related macular degeneration (AMD), but the FDA has not approved it for that purpose. 

By Nicole Gray • Jan. 19, 2016

Taiwan election results buoy biotech sector, president-elect seen as major ally

President-elect Tsai Ing-wen has said that she wishes to boost Taiwan's biotechnology industry. 

By Nicole Gray • Jan. 19, 2016

Pfizer CEO: Our CAR-T development method could give us a leg up over Kite, Juno, Novartis

"None of the other companies have that capability," said Pfizer chief Ian Read at the JPMorgan Healthcare Conference, referring to partner Cellectis' more universal approach to CAR-T.

By Sy Mukherjee • Jan. 14, 2016

Bayer opens OTC drug manufacturing plant in China

The plant is Bayer's second-largest facility in the Asia-Pacific region, and will produce OTC drugs and traditional Chinese medicines. 

By Ned Pagliarulo • Jan. 14, 2016

Warning letters reveal some of the FDA's biggest problems with Indian drugmakers

Nearly a third of the warning letters issued by the FDA's Center for Drug Evaluation and Research stemmed from violations of safe manufacturing practices at India-based facilities. 

By Ned Pagliarulo • Jan. 13, 2016

FDA flags manufacturing deficiencies of Chinese drug supplier

The warning letter from the FDA reveals Zhejiang Hisun Pharmaceutical had been the subject of 61 complaints from 2012 to 2014.

By Ned Pagliarulo • Jan. 13, 2016

Baxter again forced to recall IV solutions due to insect presence

About 284,000 units of Baxter's intravenous solution have been recalled. 

By Nicole Gray • Jan. 12, 2016

Allergan acquires Anterios to enhance neurotoxin delivery, bolsters Botox portfolio

Anterios' platform enables Botox and other neurotoxins to be delivered through the skin, rather than by injection. 

By Nicole Gray • Jan. 12, 2016

J&J may sell off its Noramco manufacturing unit in $800 million deal

That's according to sources familiar with the situation, Reuters reports. The unit produces active ingredients for painkillers.

By Sy Mukherjee • Jan. 7, 2016

India's Cadila to snap up plant, animal health products from Pfizer spinoff Zoetis

Cadila will pay $29 million in a deal expected to close sometime in the first quarter. 

By Ned Pagliarulo • Jan. 7, 2016

3 key biopharma manufacturing stories to keep an eye on in 2016

From compliance issues abroad to the developmental challenges of groundbreaking new therapies, here are some of the most important issues to watch in the world of biopharma manufacturing in the coming year.

By Sy Mukherjee • Jan. 7, 2016

In efficiency bid, Novartis selling Alcon unit to Recipharm in $20M deal

Recipharm will expand its presence in France—one of its seven key operational regions. 

By Nicole Gray • Jan. 7, 2016

The year ahead: 11 execs & experts predict what's in store for biopharma in 2016

With a record-setting year behind us, we can only imagine what’s ahead for the industry in the coming months. Fortunately, industry execs and experts from Sanofi, Boehringer, Bain, amfAR, Novocure, and others shared some of their own predictions with BioPharma Dive.

By Nicole Gray • Jan. 4, 2016

11 biopharma execs & experts look back on 2015: A record year for record-breaking

We spoke with bigwigs from Sanofi, the Biosimilars Council, Novocure, Accenture, Bain, amfAR, Boehringer Ingelheim, and more on what they considered the most significant events that drove biopharma this past year.

By Nicole Gray • Dec. 22, 2015

With eye on the future, AstraZeneca to beef up manufacturing, R&D presence in China

Investing directly in manufacturing and R&D capabilities in the country is seen as critical for future drug approvals in the market. 

By Nicole Gray • Dec. 17, 2015

Mylan to Strides: Help us cover the tab for your noncompliant plants

There were signs of problems at several Bangalore-based facilities before Mylan acquired Strides Arcolabs in late 2014. 

By Nicole Gray • Dec. 16, 2015